Population-based study of risk of breast cancer in carriers of BRCA2 mutation

Lancet

Volumn 352, Issue 9137, 1998, Pages 1337-1339

  Thorlacius, Steinunn ^a   Struewing, Jeffery P ^c   Hartge, Patricia ^c   Olafsdottir, Gudridur H ^b   Sigvaldason, Helgi ^b   Tryggvadottir, Laufey ^b   Wacholder, Sholom ^c   Tulinius, Hrafn ^b   Eyfjörd, Jorunn E ^a,d  

^a Icelandik Cancer Society   (Iceland)

^b ICELANDIC CANCER REGISTRY   (Iceland)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ICELANDIC CANCER SOCIETY   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER RISK; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; ICELAND; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PEDIGREE; POPULATION RESEARCH; PRIORITY JOURNAL;

EID: 18344410703     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03300-5     Document Type: Article

References (25)

1. 1 Miki Y, Swensen J, Scattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
2. 2 Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
3. 3 Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12: 333-37.
4. 4 Couch FJ, Weber BL. Mutations and polymorphisms in the familiar early-onset breast cancer (BRCA1) gene: Breast Cancer Information Core. Hum Mutat 1996; 8: 8-18.
5. 5 Easton DF, Ford D, Bishop DT. Breast Cancer Linkage Consortium: breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995; 56: 265-71.
6. 6 Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-89.
7. 7 Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-08.
8. 8 Fodor F, Weston A, Bleiweiss IJ, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998; 63: 45-51.
9. 9 Gayther SA, Warren W, Mazoyer A, et al. Germline mutations of the BRCA1 gene in breast cancer and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995; 11: 428-33.
10. 10 Holt JT, Thompson ME, Szabo C, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996; 12: 298-302.
11. 11 Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast cancer and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997; 15: 103-05.
12. 12 Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185de1AG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11: 198-200.
13. 13 Roa BB, Boyd AA, Volick J, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 185-87.
14. 14 Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996; 14: 188-90.
15. 15 Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13: 117-19.
16. 16 Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996; 56: 3663-65.
17. 17 Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997; 60: 1079-84.
18. 18 Bergthorsson JT, Jonasdottir A, Johannesdottir G, et al. Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat 1998; 6 (suppl): S195-97.
19. 19 Tulinius H, Sigvaldason H, Olafsdottir G, Tryggvadottir L. Epidemiology of breast cancer in families in Iceland. J Med Genet 1992; 29: 158-64.
20. 20 Jonasson JG, Agnarsson B, Thorlacius S, Eyfjörd JE, Tulinius H. Male breast cancer in Iceland. Int J Cancer 1996; 65: 446-49.
21. 21 Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997; 60: 1059-67.
22. 22 Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996; 347: 1643-45.
23. 23 Thorlacius S, Tryggvadottir L, Olafsdottir G, et al. Linkage to BRCA2 region in hereditary male breast cancer. Lancet 1995; 346: 544-45.
24. 24 Anon. Cancer incidence in five continents, vol VII. Lyon: IARC Sci Publ no 143, 1997: 514-17.
25. 25 Bjarnason O. Iceland. In: Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Berlin: Springer-Verlag, 1966: 168-78.